
Stephen Holt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2182/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Medicine, 2001, 27, 803-811.	8.2	245
2	A Causative Role for Redox Cycling of Myoglobin and Its Inhibition by Alkalinization in the Pathogenesis and Treatment of Rhabdomyolysis-induced Renal Failure. Journal of Biological Chemistry, 1998, 273, 31731-31737.	3.4	234
3	Serum Calcification Propensity Predicts All-Cause Mortality in Predialysis CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 339-348.	6.1	198
4	Aortic Stiffness Is Independently Associated With Rate of Renal Function Decline in Chronic Kidney Disease Stages 3 and 4. Hypertension, 2010, 55, 1110-1115.	2.7	184
5	Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature, 2017, 545, 243-247.	27.8	181
6	Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3357-3365.	3.6	178
7	Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet, The, 1999, 353, 294-295.	13.7	165
8	Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrology Dialysis Transplantation, 2012, 27, 1957-1966.	0.7	156
9	A chemiluminescense-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols. Free Radical Research, 2000, 32, 1-9.	3.3	153
10	Spectrum of chronic kidney disease in HIVâ€infected patients. HIV Medicine, 2009, 10, 329-336.	2.2	140
11	Fetuin-A-Containing Calciprotein Particles Reduce Mineral Stress in the Macrophage. PLoS ONE, 2013, 8, e60904.	2.5	138
12	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I – Assessment and Management of Various Cardiovascular Risk Factors. Peritoneal Dialysis International, 2015, 35, 379-387.	2.3	123
13	Predictors of Renal Outcome in HIVâ€Associated Nephropathy. Clinical Infectious Diseases, 2008, 46, 1282-1289.	5.8	103
14	Increased sensitivity to endotoxemia in the bile duct-ligated cirrhotic rat. Hepatology, 1999, 30, 1198-1205.	7.3	100
15	Review article: vitamin <scp>D</scp> and inflammatory bowel disease – established concepts and future directions. Alimentary Pharmacology and Therapeutics, 2012, 36, 324-344.	3.7	91
16	Acute cholestasis-induced renal failure: Effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney International, 1999, 55, 271-277.	5.2	81
17	Serum fetuinâ€ <scp>A</scp> concentration and fetuinâ€ <scp>A</scp> â€containing calciprotein particles in patients with chronic inflammatory disease and renal failure. Nephrology, 2013, 18, 215-221.	1.6	81
18	Atrial thrombus and central venous dialysis catheters. American Journal of Kidney Diseases, 2001, 38, 631-639.	1.9	77

#	Article	IF	CITATIONS
19	The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients. Nephrology Dialysis Transplantation, 2012, 27, 1534-1541.	0.7	77
20	FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. Scientific Reports, 2017, 7, 3345.	3.3	75
21	Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD). Nephrology Dialysis Transplantation, 2013, 28, 1569-1579.	0.7	65
22	Elastin Degradation Is Associated With Progressive Aortic Stiffening and All-Cause Mortality in Predialysis Chronic Kidney Disease. Hypertension, 2012, 59, 973-978.	2.7	63
23	A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. Scientific Reports, 2017, 7, 5686.	3.3	62
24	Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1971-1981.	2.3	55
25	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II – Management of Various Cardiovascular Complications. Peritoneal Dialysis International, 2015, 35, 388-396.	2.3	55
26	Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease. Nephrology Dialysis Transplantation, 2016, 31, 1583-1587.	0.7	55
27	FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-1² autoinduction. International Journal of Biochemistry and Cell Biology, 2017, 92, 63-78.	2.8	55
28	Progression of Tubulointerstitial Fibrosis and the Chronic Kidney Disease Phenotype – Role of Risk Factors and Epigenetics. Frontiers in Pharmacology, 2017, 8, 520.	3.5	54
29	Fibroblast growth factor 23. Annals of Clinical Biochemistry, 2014, 51, 203-227.	1.6	53
30	Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrology Dialysis Transplantation, 2010, 25, 1853-1858.	0.7	52
31	FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrology Dialysis Transplantation, 2012, 27, 727-733.	0.7	52
32	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	6.1	52
33	Biochemical transformation of calciprotein particles in uraemia. Bone, 2018, 110, 355-367.	2.9	49
34	Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Aids, 2009, 23, 2517-2521.	2.2	48
35	The role of fetuin-A in mineral trafficking and deposition. BoneKEy Reports, 2015, 4, 672.	2.7	48
36	Recent developments in HIV and the kidney. Current Opinion in Infectious Diseases, 2009, 22, 43-48.	3.1	46

#	Article	IF	CITATIONS
37	Instability of fibroblast growth factor-23 (FGF-23): Implications for clinical studies. Clinica Chimica Acta, 2011, 412, 1008-1011.	1.1	44
38	Use of a pre-analysis osmolality normalisation method to correct for variable urine concentrations and for improved metabolomic analyses. Journal of Chromatography A, 2016, 1431, 103-110.	3.7	42
39	Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis. Seminars in Dialysis, 2018, 31, 487-499.	1.3	40
40	Animal Models to Study Links between Cardiovascular Disease and Renal Failure and Their Relevance to Human Pathology. Frontiers in Immunology, 2015, 6, 465.	4.8	39
41	Deterioration of Cortical Bone Microarchitecture: Critical Component of Renal Osteodystrophy Evaluation. American Journal of Nephrology, 2018, 47, 376-384.	3.1	39
42	Epigenetic Modifications to H3K9 in Renal Tubulointerstitial Cells after Unilateral Ureteric Obstruction and TGF-β1 Stimulation. Frontiers in Pharmacology, 2017, 8, 307.	3.5	38
43	Poor agreement between commercial ELISAs for plasma fetuin-A: An effect of protein glycosylation?. Clinica Chimica Acta, 2010, 411, 1367-1370.	1.1	35
44	Further Evidence for an Interaction between Alcohol and Certain H2-Receptor Antagonists. Alcoholism: Clinical and Experimental Research, 1991, 15, 1084-1085.	2.4	31
45	The effect of increasing dialysate magnesium on calciprotein particles, inflammation and bone markers: <i>post hoc</i> analysis from a randomized controlled clinical trial. Nephrology Dialysis Transplantation, 2021, 36, 713-721.	0.7	30
46	The importance of klotho in phosphate metabolism and kidney disease. Nephrology, 2014, 19, 439-449.	1.6	29
47	Peritoneal dialysis practice in Australia and New Zealand: A call to sustain the action. Nephrology, 2016, 21, 535-546.	1.6	29
48	An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis. Journal of Materials Science: Materials in Medicine, 2014, 25, 1589-1597.	3.6	28
49	Peritoneal Dialysis for Heart Failure. Peritoneal Dialysis International, 2015, 35, 645-649.	2.3	27
50	TGF-β1 modifies histone acetylation and acetyl-coenzyme A metabolism in renal myofibroblasts. American Journal of Physiology - Renal Physiology, 2019, 316, F517-F529.	2.7	27
51	Magnetic resonance imaging based assessment of bone microstructure as a non-invasive alternative to histomorphometry in patients with chronic kidney disease. Bone, 2018, 114, 14-21.	2.9	26
52	Acute transplant rejection induced by blood transfusion reaction to the Kidd blood group system. Nephrology Dialysis Transplantation, 2004, 19, 2403-2406.	0.7	25
53	Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4. Nephrology Dialysis Transplantation, 2009, 24, 3751-3755.	0.7	24
54	Simultaneous measurement of urinary albumin and total protein may facilitate decisionâ€making in <scp>HIV</scp> â€infected patients with proteinuria. HIV Medicine, 2012, 13, 526-532.	2.2	24

#	Article	IF	CITATIONS
55	Summary of the 5th Edition of the Renal Association Clinical Practice Guidelines (2009–2012). Nephron Clinical Practice, 2011, 118, c27-c70.	2.3	23
56	High-intensity physical exercise increases serum <i>α</i> -klotho levels in healthy volunteers. Journal of Circulating Biomarkers, 2018, 7, 184945441879458.	1.3	23
57	Diagnostic Tests for Vascular Calcification. Advances in Chronic Kidney Disease, 2019, 26, 445-463.	1.4	23
58	Green dialysis survey: Establishing a baseline for environmental sustainability across dialysis facilities in Victoria, Australia. Nephrology, 2019, 24, 88-93.	1.6	22
59	Fetuinâ€ <scp>A</scp> â€containing calciprotein particle levels can be reduced by dialysis, sodium thiosulphate and plasma exchange. Potential therapeutic implications for calciphylaxis?. Nephrology, 2013, 18, 724-727.	1.6	21
60	αKlotho–FGF23 interactions and their role in kidney disease: a molecular insight. Cellular and Molecular Life Sciences, 2019, 76, 4705-4724.	5.4	21
61	The Gut in Older Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2015, 35, 650-654.	2.3	20
62	The Role of Secondary Calciprotein Particles in the Mineralisation Paradox of Chronic Kidney Disease. Calcified Tissue International, 2017, 101, 570-580.	3.1	19
63	Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. Nature Communications, 2022, 13, .	12.8	19
64	A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy, 2014, 11, 35.	1.7	16
65	Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism. BMC Nephrology, 2018, 19, 113.	1.8	16
66	Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized ControlledÂTrial. Kidney International Reports, 2020, 5, 1432-1447.	0.8	15
67	Monitoring skin temperature at the wrist in hospitalised patients may assist in the detection of infection. Internal Medicine Journal, 2020, 50, 685-690.	0.8	15
68	Renal Association Clinical Practice Guideline on Cardiovascular Disease in CKD. Nephron Clinical Practice, 2011, 118, c125-c144.	2.3	14
69	Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients. European Journal of Clinical Nutrition, 2017, 71, 180-184.	2.9	13
70	Assessing the utility of testing aluminum levels in dialysis patients. Hemodialysis International, 2015, 19, 256-262.	0.9	12
71	Relative abundance of fetuin― <scp>A</scp> in peritoneal dialysis effluent and its association with in situ formation of calciprotein particles: An observational pilot study. Nephrology, 2015, 20, 6-10.	1.6	12
72	Nanoflow-Nanospray Mass Spectrometry Metabolomics Reveals Disruption of the Urinary Metabolite Profiles of HIV-Positive Patients on Combination Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e45-e53.	2.1	12

#	Article	IF	CITATIONS
73	Soluble klotho may be a marker of phosphate reabsorption. CKJ: Clinical Kidney Journal, 2017, 10, 397-404.	2.9	12
74	Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism. Nephrology, 2017, 22, 47-50.	1.6	11
75	Calciprotein Particle Formation in Peritoneal Dialysis Effluent is Dependent on Dialysate Calcium Concentration. Peritoneal Dialysis International, 2018, 38, 286-292.	2.3	11
76	Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody. BMC Nephrology, 2021, 22, 198.	1.8	11
77	An analysis of antibody responses and clinical sequalae of the Sinopharm <scp>HB02 COVID19</scp> vaccine in dialysis patients in the <scp>United Arab Emirates</scp> . Nephrology, 2022, 27, 260-268.	1.6	11
78	Is serum phosphate a useful target in patients with chronic kidney disease and what is the role for dietary phosphate restriction?. Nephrology, 2017, 22, 36-41.	1.6	10
79	Aortic stiffness and central systolic pressure are associated with ambulatory orthostatic BP fall in chronic kidney disease. Journal of Nephrology, 2020, 33, 317-324.	2.0	10
80	Important Differences in Measurement of Fetuin-A. Annals of Internal Medicine, 2010, 153, 419.	3.9	9
81	Patent foramen ovale, dialysis and microembolization. Nephrology, 2012, 17, 569-574.	1.6	9
82	Large vessel calcification in <scp>T</scp> akayasu arteritis. Internal Medicine Journal, 2013, 43, 584-587.	0.8	9
83	Increasing home dialysis knowledge through a webâ€based eâ€learning program. Nephrology, 2014, 19, 345-351.	1.6	9
84	Relationship between timed and spot urine collections for measuring phosphate excretion. International Urology and Nephrology, 2016, 48, 115-124.	1.4	9
85	Changes in bone microarchitecture following kidney transplantation—Beyond bone mineral density. Clinical Transplantation, 2018, 32, e13347.	1.6	9
86	Outcomes of cinacalcet withdrawal in Australian dialysis patients. Internal Medicine Journal, 2019, 49, 48-54.	0.8	9
87	Alcoholic hepatitisthe case for intensive management. Postgraduate Medical Journal, 2000, 76, 504-507.	1.8	8
88	Treatment of unilateral obstruction reversing heavy and bilateral proteinuria. Nephrology Dialysis Transplantation, 2005, 20, 210-212.	0.7	8
89	Diurnal variation and short-term pre-analytical stability of serum soluble $\hat{I}\pm$ -klotho in healthy volunteers: a pilot study. Annals of Clinical Biochemistry, 2015, 52, 506-509.	1.6	8
90	Emerging role of highâ€resolution imaging in the detection of renal osteodystrophy. Nephrology, 2016, 21, 801-811.	1.6	8

#	Article	IF	CITATIONS
91	Cytokine nephropathy and multi-organ dysfunction in lymphoma. Nephrology Dialysis Transplantation, 1998, 13, 1853-1857.	0.7	7
92	The challenge of germ cell tumour therapy in dialysis and transplantation. Nephrology Dialysis Transplantation, 2005, 20, 2867-2868.	0.7	7
93	Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study. BMC Nephrology, 2012, 13, 40.	1.8	7
94	Renal allograft re-use and herpetic re-infection. Nephrology, 2015, 20, 17-21.	1.6	7
95	Hodgkin's Lymphoma Diagnosed from Peritoneal Effluent. Peritoneal Dialysis International, 2016, 36, 350-351.	2.3	7
96	Platelet counts in autosomal dominant polycystic kidney disease. Platelets, 2016, 27, 262-263.	2.3	7
97	Introduction of Renal Key Performance Indicators Associated with Increased Uptake of Peritoneal Dialysis in a Publicly Funded Health Service. Peritoneal Dialysis International, 2017, 37, 198-204.	2.3	7
98	An In Vitro Murine Model of Vascular Smooth Muscle Cell Mineralization. Methods in Molecular Biology, 2016, 1397, 209-220.	0.9	7
99	Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. BMJ Case Reports, 2011, 2011, bcr0520114287-bcr0520114287.	0.5	6
100	Impact of cinacalcet preâ€ŧransplantation on mineral metabolism in renal transplant recipients. Nephrology, 2016, 21, 46-54.	1.6	6
101	Fetuin-A in the peritoneal effluent of patients with encapsulating peritoneal sclerosis—more than a protein?. Kidney International, 2017, 92, 1289-1290.	5.2	6
102	Changes in Markers of Mineral Metabolism After Living Kidney Donation. Transplantation Direct, 2017, 3, e150.	1.6	6
103	Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney disease. BMC Nephrology, 2020, 21, 279.	1.8	6
104	Inferiority of arteriovenous grafts, in comparison to autogenous fistulas, is underestimated by standard survival measures alone. ANZ Journal of Surgery, 2021, 91, 162-167.	0.7	6
105	Is the kidney just a modified blood vessel? Unravelling the direction of causality between cardiovascular and renal disease. Atherosclerosis, 2011, 216, 275-276.	0.8	5
106	Liver disease and renal dysfunction. Medicine, 2011, 39, 492-496.	0.4	5
107	FGF23 adds value to risk prediction in patients with chronic kidney disease. Bone, 2012, 51, 830-831.	2.9	5
108	Climate change and us: What nephrologists should know. Nephrology, 2015, 20, 760-764.	1.6	5

Stephen Holt

#	Article	IF	CITATIONS
109	Reduction of Calciprotein Particles in Adults Receiving Infliximab for Chronic Inflammatory Disease. JBMR Plus, 2021, 5, e10497.	2.7	5
110	The Introduction of cPRA and Its Impact on Access to Deceased Donor Kidney Transplantation for Highly Sensitized Patients in Australia. Transplantation, 2021, 105, 1317-1325.	1.0	5
111	The potential role of antibodies against minor blood group antigens in renal transplantation. Transplant International, 2020, 33, 841-848.	1.6	4
112	Hepatitis B related dilemmas in the renal unit. Nephrology, 2021, 26, 287-293.	1.6	4
113	Granulomatous interstitial nephritis treated with a tumour necrosis factor-α inhibitor. Nephrology Dialysis Transplantation, 2006, 21, 2311-2314.	0.7	3
114	The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 1752-1753.	0.7	3
115	Does a Patent Foramen Ovale Influence Cognitive Function in Dialysis Patients?. Nephron Clinical Practice, 2013, 123, 1-6.	2.3	3
116	Thalidomide-induced heart block in a dialysis patient. CKJ: Clinical Kidney Journal, 2009, 2, 507-508.	2.9	2
117	Hyperparathyroidism in chronic kidney disease: complexities within the commonplace. Clinical Medicine, 2012, 12, 333-337.	1.9	2
118	The value of urinary neutrophil gelatinase-associated lipocalin in risk prediction of renal decline in patients with chronic kidney disease. Kidney International, 2013, 84, 216-217.	5.2	2
119	Profiling histone modifications in the normal mouse kidney and after unilateral ureteric obstruction. American Journal of Physiology - Renal Physiology, 2019, 317, F606-F615.	2.7	2
120	Noninfectious mixed cryoglobulinaemic glomerulonephritis and monoclonal gammopathy of undetermined significance: a coincidental association?. BMC Nephrology, 2020, 21, 293.	1.8	2
121	Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3–4 CKD—results from a placebo-controlled randomized trial. Nephrology Dialysis Transplantation, 2023, 38, 344-351.	0.7	2
122	The Omicron <scp>COVID</scp> â€19 threat to dialysis patients is dramatically lower than previous variants. Nephrology, 2022, 27, 725-726.	1.6	2
123	The National Health Service Breast Screening Programme in the Trent region—are we meeting the targets?. European Journal of Surgical Oncology, 1998, 24, 99-103.	1.0	1
124	Dialysis independence following radiotherapy of renal extramedullary haemopoeisis. Nephrology Dialysis Transplantation, 2004, 19, 1310-1312.	0.7	1
125	Liver disease and renal dysfunction. Medicine, 2007, 35, 521-523.	0.4	1
126	FGF23: instability may affect accuracy and interpretation. Osteoporosis International, 2013, 24, 1135-1136.	3.1	1

#	Article	IF	CITATIONS
127	Old tracer for a new purpose. Nuclear Medicine Communications, 2014, 35, 1058-1066.	1.1	1
128	Renal and Hepatic Kinetics of Tc-99m-labelled Hexakis-methoxy-isobutyl Isonitrile. Drug Metabolism Letters, 2013, 6, 242-246.	0.8	1
129	Rhabdomyolysis and Compartment Syndrome. Competency-based Critical Care, 2008, , 38-41.	0.0	1
130	Providing a Peritoneal Dialysis Service. , 2014, , 705-716.		1
131	Relationship Between Urinary Phosphate and All-Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study. , 2021, , .		1
132	The reappearing kidney: an unusual complication of renal biopsy. Nephrology Dialysis Transplantation, 1999, 14, 1758-1760.	0.7	0
133	Renal involvement in an Anderson-Fabry heterozygote. Postgraduate Medical Journal, 2002, 78, 759-759.	1.8	0
134	The potential usefulness of vitamin C as an anti-oxidant?. Intensive Care Medicine, 2002, 28, 1186-1186.	8.2	0
135	Response to Macrocirculation Meets Microcirculation. Hypertension, 2010, 56, .	2.7	0
136	Factors associated with increasing vascular stiffness in PD. Nephrology Dialysis Transplantation, 2011, 26, 2060-2061.	0.7	0
137	C-terminal FGF23 fragments: present but not seen?. Osteoporosis International, 2013, 24, 1933-1934.	3.1	0
138	FP061IS THROMBOCYTOPAENIA IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE REAL ?. Nephrology Dialysis Transplantation, 2015, 30, iii84-iii85.	0.7	0
139	SP658EFFECTS OF CINACALCET USE ON POST TRANSPLANT MINERAL METABOLISM. Nephrology Dialysis Transplantation, 2015, 30, iii595-iii595.	0.7	0